Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study was designed to evaluate the pharmacokinetic profile, safety and efficacy in Parkinson's Disease patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ropinirole PR/XR | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ropinirole prolonged release/extended release(PR/XR) | Drug | Subjects will take the investigational drug once daily at the same time each day, it is recommended that this is in the morning for optimal benefit. Investigational drug is taken for 52 weeks, starting on the next day of the Week 0 visit. One tablet of ropinirole PR/XR 2 mg tablets will be orally dosed as the initial dose. The dose will be titrated weekly by 2 mg/day, and increased to 8 mg/day in Week 4. From Week 5 up to 16, the dose will be increased at minimum intervals of one week between titration steps until sufficient efficacy is obtained, according to individual clinical response and tolerability (the dose may be titrated up to 16 mg/day). In Week 16 and further, treatment dose at Week 16 will be continuously administered up to Week 52. If insufficient efficacy is judged in a subject during treatment, or unable to maintain the dose due to adverse event, the treatment dose may be changed. The dose is down tapered according to the maintenance dose at Week 52 (or withdrawal). |
| Measure | Description | Time Frame |
|---|---|---|
| Food Effects on Cmax and Cmin of SKF101468 (Ropinirole) and Its Metabolites | The dose of SKF101468 and its metabolites was normalized to 1 mg. Blood sampling at steady state up to 24 hours post dose after receiving the maintenance dose was conducted. In order to investigate the effect of a meal on pharmacokinetics, blood was sampled twice (after a standard morning meal and at fasted state) from identical participants. Cmax: maximum concentration, Cmin: trough plasma concentration. | Weeks 5-16 |
| Food Effects on AUC0-24 of SKF101468 (Ropinirole) and Its Metabolites | The dose of SKF101468 and its metabolites was normalized to 1 mg. Blood sampling at steady state up to 24 hours (hr) post dose after receiving the maintenance dose was conducted. In order to investigate the effect of a meal on pharmacokinetics, blood was sampled twice (after a standard morning meal and at fasted state) from identical participants. AUC0-24: area under the drug concentration 24 hr curve. | Weeks 5-16 |
| Food Effects on Tmax of SKF101468 (Ropinirole) and Its Metabolites | The dose of SKF101468 and its metabolites was normalized to 1 mg. Blood sampling at steady state up to 24 hours post dose after receiving the maintenance dose was conducted. In order to investigate the effect of a meal on pharmacokinetics, blood was sampled twice (after a standard morning meal and at fasted state) from identical participants. Tmax: time of maximum concentration. Data are presented as the median difference between fed and fasted states for ropinirole and each metabolite. | Weeks 5-16 |
| Plasma Trough Concentrations of SKF101468 (Ropinirole) and Its Metabolites | Blood sampling in the fixed titration phase will be performed at 24 hour post dose of the last dose of 2, 4, and 8 mg (immediately before the morning dose). Blood sampling in the maintenance dose phase will be performed at 24 hour post dose of 10 mg or more for one week or longer (immediately before the morning dose), as sampling needs to be conducted at steady state. |
| Measure | Description | Time Frame |
|---|---|---|
| Total Score in the Japanese UPDRS Part III | The Unified Parkinson's Disease Rating Scale (UPDRS) assesses the status of Parkinson's Disease (PD) patients objectively. The Japanese UPDRS Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per each item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. | Weeks 0-52 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients who present serious physical signs and symptoms other than those of the PD (e.g. cardiac/hepatic/renal disorder and haematopoietic disorder). The seriousness refers to Grade 3 according to "the Classification of the Severity of Adverse Experiences (Pharmaceutical affairs bureau/Safety division (PAB/SD) Notification No. 80, dated 29 June 1992).
Patients with symptomatic postural hypotension. (e.g. dizziness and syncope).
Patients who have had serious psychiatric symptoms (e.g. confusion, hallucination, delusion, abnormal behaviour, alcohol or drug dependence) during the past six months (26 weeks) (including symptoms caused by anti-Parkinson drugs).
Patients who have been treated with the following drugs at Week -4, and whose treatment regimen of the drug has been changed from Week -4 to Week 0.
Patients with severe dementia such as score 3 or 4 of the UPDRS Part I (Mentation, behaviour, and mood)
Female patients who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study or within 30 days after the last dose of the study drug.
Patients with current history or complication of carcinoma or malignant tumour.
Patients who have history of drug allergy to ropinirole hydrochloride (HCl).
Patients who have received surgical treatment for PD in the past (e.g. pallidectomy, deep brain stimulation).
Patients who have been treated with any other investigational drug within 12weeks prior to the treatment phase.
Others whom the investigator (sub investigator) considers ineligible for the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Aichi | 455-8530 | Japan | |||
| GSK Investigational Site |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Ropinirole PR/XR | Treatment Phase: Fixed titration phase (4 weeks): one tablet of ropinirole PR/XR 2 milligrams (mg) as the initial dose. The dose was titrated weekly by 2 mg/day and was increased to 8 mg/day in Week 4; Flexible titration and maintenance dose phases (48 weeks): from Week 5 up to Week 16, the dose was increased at minimum intervals of 1 week between titration steps (up to 16 mg/day). From Week 16 onward, treatment dose was continuously administered up to Week 52. Taper phase: the dose was tapered over 2 to 3 weeks according to the maintenance dose at completion of the Treatment Phase (or withdrawal) |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Ropinirole PR/XR | Treatment Phase: Fixed titration phase (4 weeks): one tablet of ropinirole PR/XR 2 milligrams (mg) as the initial dose. The dose was titrated weekly by 2 mg/day and was increased to 8 mg/day in Week 4; Flexible titration and maintenance dose phases (48 weeks): from Week 5 up to Week 16, the dose was increased at minimum intervals of 1 week between titration steps (up to 16 mg/day). From Week 16 onward, treatment dose was continuously administered up to Week 52. Taper phase: the dose was tapered over 2 to 3 weeks according to the maintenance dose at completion of the Treatment Phase (or withdrawal) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Food Effects on Cmax and Cmin of SKF101468 (Ropinirole) and Its Metabolites | The dose of SKF101468 and its metabolites was normalized to 1 mg. Blood sampling at steady state up to 24 hours post dose after receiving the maintenance dose was conducted. In order to investigate the effect of a meal on pharmacokinetics, blood was sampled twice (after a standard morning meal and at fasted state) from identical participants. Cmax: maximum concentration, Cmin: trough plasma concentration. | Pharmacokinetic (PK) Population: participants who underwent blood sampling for PK research, excluding those who did not fulfill inclusion criteria and those who were considered to affect the evaluation of the PK research due to drug incompliance or other protocol violation. | Posted | Geometric Mean | 95% Confidence Interval | picograms/milliliter (pg/mL) | Weeks 5-16 |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Ropinirole PR/XR (Treatment Phase) | Fixed titration phase (4 weeks): one tablet of ropinirole PR/XR 2 mg as the initial dose. The dose was titrated weekly by 2 mg/day and was increased to 8 mg/day in Week 4; Flexible titration and maintenance dose phases (48 weeks): from Week 5 up to Week 16, the dose was increased at minimum intervals of 1 week between titration steps (up to 16 mg/day). From Week 16 onward, treatment dose was continuously administered up to Week 52. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Ovarian neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | MedDRA | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| GSK Response Center | GlaxoSmithKline | 866-435-7343 |
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Weeks 1-16 |
| Change From Baseline in the Japanese UPDRS Part III | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per each item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. | Baseline (Week 0) and Weeks 1-52 |
| Percent Change From Baseline in the Japanese UPDRS Part III | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per each item. A maximum total score is 108 points.The higher score indicates more severe PD symptoms. | Baseline (Week 0) and Weeks 1-52 |
| Percentage of Responders of the Total Score in the Japanese UPDRS Total Score in Part III | A responder is defined as a participant with a 30% or more reduction at baseline. The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per each item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. | Baseline (Week 0) and Weeks 1-52 |
| Total Score in the Japanese UPDRS Part I | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per each item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. | Weeks 0-52 |
| Change From Baseline in the Japanese UPDRS Part I | The UPDRS (Unified Parkinson's Disease Rating Scale) assesses the status of PD patients objectively. The Japanese UPDRS Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per each item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. | Baseline (Week 0) and Weeks 1-52 |
| Percent Change From Baseline in the Japanese UPDRS Part I | The UPDRS (Unified Parkinson's Disease Rating Scale) assesses the status of PD patients objectively. The Japanese UPDRS Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per each item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. | Baseline (Week 0) and Weeks 1-52 |
| Total Score in the Japanese UPDRS Part II | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per each item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. | Weeks 0-52 |
| Change From Baseline in the Japanese UPDRS Part II | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per each item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. | Baseline (Week 0) and Weeks 1-52 |
| Percent Change From Baseline in the Japanese UPDRS Part II | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per each item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. | Baseline (Week 0) and Weeks 1-52 |
| Total Score in the Japanese UPDRS Part IV | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per each item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. | Baseline (Week 0) and Weeks 0-52 |
| Change From Baseline in the Japanese UPDRS Part IV | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per each item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. | Baseline (Week 0) and Weeks 1-52 |
| Percent Change From Baseline in the Japanese UPDRS Part IV | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per each item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. | Baseline (Week 0) and Weeks 1-52 |
| Summary of the Modified Hoehn & Yahr Criteria Stages | Hoehn & Yahr criteria were measured on an 8-point scale. 0: No signs of disease, 1: Unilateral disease, 1.5: Unilateral plus axial involvement, 2: Bilateral disease, 2.5: Mild bilateral disease, 3: Mild to moderate bilateral disease. No subjects evaluated had a score of 4 (severe disability) or 5 (wheelchair bound or bedridden unless aided). | Screening-Week 52 |
| Number of Participants Scored as Responders on the Clinician's Global Impression (CGI) Scale | CGI is measured on a 7-point scale. 1: Very much improved, 2: Much Improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse. Responders are defined as those participants scored as "very much improved" or "much improved." | Weeks 1-52 |
| Percentage of Participants Who Remained in the Study on the Indicated Days | The percentage of participants remaining in the study was examined using the Kaplan-Meier method, in which a premature discontinuation will be considered as an event. | Days 0-364 |
| Change From Baseline in Albumin, Total Protein, and Hemoglobin at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Baseline (Screening) and Weeks 16 and 52 |
| Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase, and Lactate Dehydrogenase at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Baseline (Screening) and Weeks 16 and 52 |
| Change From Baseline in Total Bilirubin, Blood Urea Nitrogen, and Creatinine at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Baseline (Screening) and Weeks 16 and 52 |
| Change From Baseline in Blood Urea Nitrogen, Cholesterol, Chloride, Potassium, and Sodium at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Baseline (Screening) and Weeks 16 and 52 |
| Change From Baseline in Prolactin at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Baseline (Screening) and Weeks 16 and 52 |
| Change From Baseline in Hematocrit at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Baseline (Screening) and Weeks 16 and 52 |
| Change From Baseline in Platelet Count and White Blood Cell Count at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Baseline (Screening) and Weeks 16 and 52 |
| Change From Baseline in Red Blood Cell Count at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Baseline (Screening) and Weeks 16 and 52 |
| Urinalysis Data | The number of participants with the indicated dipstick test values were measured. Dipstick test values: Neg Value, Trace, +1, +2, +3, +4. No participants had a score of +5. | Screening, Week 16, and Week 52 |
| Number of Participants With the Indicated Shift From Baseline in 12-Lead Electrocardiogram (ECG) Findings at Weeks 16 and 52 | Baseline Finding/Time Period Finding. Abbreviations: N = normal; A = abnormal; CS = clinically significant; NCS = not clinically significant. Options include N/N, N/ANCS, N/ACS, ANCS/N, ANCS/ANCS, ANCS/ACS, ACS/N, ACS/ANCS, and ACS/ACS. | Baseline (Screening) and Weeks 16 and 52 |
| Change From Baseline in Supine and Standing Systolic and Diastolic Blood Pressure at Weeks 16 and 52 | Change from baseline was calculated as Week 16 and Week 52 values minus baseline values. | Baseline (Screening) and Weeks 16 and 52 |
| Change From Baseline in Supine and Standing Pulse Rate at Weeks 16 and 52 | Change from baseline was calculated as Week 16 and Week 52 values minus baseline values. | Baseline (Screening) and Weeks 16 and 52 |
| Aichi |
| 460-0008 |
| Japan |
| GSK Investigational Site | Chiba | 279-0021 | Japan |
| GSK Investigational Site | Ehime | 791-0295 | Japan |
| GSK Investigational Site | Hokkaido | 070-0901 | Japan |
| GSK Investigational Site | Kanagawa | 251-0038 | Japan |
| GSK Investigational Site | Kyoto | 600-8811 | Japan |
| GSK Investigational Site | Numakunai | 020-0878 | Japan |
| GSK Investigational Site | Osaka | 570-8507 | Japan |
| GSK Investigational Site | Saitama | 343-0032 | Japan |
| GSK Investigational Site | Tokyo | 113-8431 | Japan |
| GSK Investigational Site | Tokyo | 136-0075 | Japan |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Number | participants |
|
|
|
| Secondary | Total Score in the Japanese UPDRS Part III | The Unified Parkinson's Disease Rating Scale (UPDRS) assesses the status of Parkinson's Disease (PD) patients objectively. The Japanese UPDRS Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per each item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. | Full Analysis Set (FAS): all participants who progressed to the treatment phase, excluding those who did not fulfill major registration criteria, those who had not received at least one dose of the investigational drug, and those whose measured data were not available after treatment initiation. Participants dropped out of the study each week. | Posted | Mean | Standard Deviation | points on a scale | Weeks 0-52 |
|
|
|
| Secondary | Change From Baseline in the Japanese UPDRS Part III | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per each item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. | FAS. Participants dropped out of the study each week. | Posted | Mean | Standard Deviation | points on a scale | Baseline (Week 0) and Weeks 1-52 |
|
|
|
| Secondary | Percent Change From Baseline in the Japanese UPDRS Part III | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per each item. A maximum total score is 108 points.The higher score indicates more severe PD symptoms. | FAS. Participants dropped out of the study each week. | Posted | Mean | Standard Deviation | percent change | Baseline (Week 0) and Weeks 1-52 |
|
|
|
| Secondary | Percentage of Responders of the Total Score in the Japanese UPDRS Total Score in Part III | A responder is defined as a participant with a 30% or more reduction at baseline. The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per each item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. | FAS. Participants dropped out of the study each week. | Posted | Number | percentage of responders | Baseline (Week 0) and Weeks 1-52 |
|
|
|
| Secondary | Total Score in the Japanese UPDRS Part I | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per each item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. | FAS. Participants dropped out of the study each week. | Posted | Mean | Standard Deviation | points on a scale | Weeks 0-52 |
|
|
|
| Secondary | Change From Baseline in the Japanese UPDRS Part I | The UPDRS (Unified Parkinson's Disease Rating Scale) assesses the status of PD patients objectively. The Japanese UPDRS Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per each item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. | FAS. Participants dropped out of the study each week. | Posted | Mean | Standard Deviation | points on a scale | Baseline (Week 0) and Weeks 1-52 |
|
|
|
| Secondary | Percent Change From Baseline in the Japanese UPDRS Part I | The UPDRS (Unified Parkinson's Disease Rating Scale) assesses the status of PD patients objectively. The Japanese UPDRS Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per each item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. | FAS. Participants dropped out of the study each week. | Posted | Mean | Standard Deviation | percent change | Baseline (Week 0) and Weeks 1-52 |
|
|
|
| Secondary | Total Score in the Japanese UPDRS Part II | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per each item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. | FAS. Participants dropped out of the study each week. | Posted | Mean | Standard Deviation | points on a scale | Weeks 0-52 |
|
|
|
| Primary | Food Effects on AUC0-24 of SKF101468 (Ropinirole) and Its Metabolites | The dose of SKF101468 and its metabolites was normalized to 1 mg. Blood sampling at steady state up to 24 hours (hr) post dose after receiving the maintenance dose was conducted. In order to investigate the effect of a meal on pharmacokinetics, blood was sampled twice (after a standard morning meal and at fasted state) from identical participants. AUC0-24: area under the drug concentration 24 hr curve. | PK Population | Posted | Geometric Mean | 95% Confidence Interval | hours*pg/mL | Weeks 5-16 |
|
|
|
| Primary | Food Effects on Tmax of SKF101468 (Ropinirole) and Its Metabolites | The dose of SKF101468 and its metabolites was normalized to 1 mg. Blood sampling at steady state up to 24 hours post dose after receiving the maintenance dose was conducted. In order to investigate the effect of a meal on pharmacokinetics, blood was sampled twice (after a standard morning meal and at fasted state) from identical participants. Tmax: time of maximum concentration. Data are presented as the median difference between fed and fasted states for ropinirole and each metabolite. | PK Population | Posted | Median | 90% Confidence Interval | hours | Weeks 5-16 |
|
|
|
| Primary | Plasma Trough Concentrations of SKF101468 (Ropinirole) and Its Metabolites | Blood sampling in the fixed titration phase will be performed at 24 hour post dose of the last dose of 2, 4, and 8 mg (immediately before the morning dose). Blood sampling in the maintenance dose phase will be performed at 24 hour post dose of 10 mg or more for one week or longer (immediately before the morning dose), as sampling needs to be conducted at steady state. | PK Population. Blood sampling was performed in all participants in the Fixed titration phase and Maintenance dose phase to measure trough concentration. The maintenance dose differs for individual participants. | Posted | Mean | Standard Deviation | pg/mL | Weeks 1-16 |
|
|
|
| Secondary | Change From Baseline in the Japanese UPDRS Part II | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per each item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. | FAS. Participants dropped out of the study each week. | Posted | Mean | Standard Deviation | points on a scale | Baseline (Week 0) and Weeks 1-52 |
|
|
|
| Secondary | Percent Change From Baseline in the Japanese UPDRS Part II | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per each item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. | FAS. Participants dropped out of the study each week. | Posted | Mean | Standard Deviation | percent change | Baseline (Week 0) and Weeks 1-52 |
|
|
|
| Secondary | Total Score in the Japanese UPDRS Part IV | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per each item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. | FAS. Participants dropped out of the study each week. | Posted | Mean | Standard Deviation | points on a scale | Baseline (Week 0) and Weeks 0-52 |
|
|
|
| Secondary | Change From Baseline in the Japanese UPDRS Part IV | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per each item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. | FAS. Participants dropped out of the study each week. | Posted | Mean | Standard Deviation | points on a scale | Baseline (Week 0) and Weeks 1-52 |
|
|
|
| Secondary | Percent Change From Baseline in the Japanese UPDRS Part IV | The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per each item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. | FAS. Participants dropped out of the study each week. | Posted | Mean | Standard Deviation | percent change | Baseline (Week 0) and Weeks 1-52 |
|
|
|
| Secondary | Summary of the Modified Hoehn & Yahr Criteria Stages | Hoehn & Yahr criteria were measured on an 8-point scale. 0: No signs of disease, 1: Unilateral disease, 1.5: Unilateral plus axial involvement, 2: Bilateral disease, 2.5: Mild bilateral disease, 3: Mild to moderate bilateral disease. No subjects evaluated had a score of 4 (severe disability) or 5 (wheelchair bound or bedridden unless aided). | FAS. Participants dropped out of the study each week. | Posted | Number | points on a scale | Screening-Week 52 |
|
|
|
| Secondary | Number of Participants Scored as Responders on the Clinician's Global Impression (CGI) Scale | CGI is measured on a 7-point scale. 1: Very much improved, 2: Much Improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse. Responders are defined as those participants scored as "very much improved" or "much improved." | FAS. Participants dropped out of the study each week. | Posted | Number | participants | Weeks 1-52 |
|
|
|
| Secondary | Percentage of Participants Who Remained in the Study on the Indicated Days | The percentage of participants remaining in the study was examined using the Kaplan-Meier method, in which a premature discontinuation will be considered as an event. | FAS. Participants dropped out of the study each week. | Posted | Number | percentage of participants | Days 0-364 |
|
|
|
| Secondary | Change From Baseline in Albumin, Total Protein, and Hemoglobin at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Safety Population: all participants who received at least one dose of study medication. Week 16 (Last observation carried forward [LOCF]) = 62 participants; Week 52 (Observed case [OC]) = 44 participants | Posted | Mean | Standard Deviation | grams per Liter (G/L) | Baseline (Screening) and Weeks 16 and 52 |
|
|
|
| Secondary | Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase, and Lactate Dehydrogenase at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Safety Population: all participants who received at least one dose of study medication. Week 16 (Last observation carried forward [LOCF]) = 62 participants; Week 52 (Observed case [OC]) = 44 participants | Posted | Mean | Standard Deviation | international units per Liter (IU/L) | Baseline (Screening) and Weeks 16 and 52 |
|
|
|
| Secondary | Change From Baseline in Total Bilirubin, Blood Urea Nitrogen, and Creatinine at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Safety Population: all participants who received at least one dose of study medication. Week 16 (Last observation carried forward [LOCF]) = 62 participants; Week 52 (Observed case [OC]) = 44 participants | Posted | Mean | Standard Deviation | micromoles per Liter (UMOL/L) | Baseline (Screening) and Weeks 16 and 52 |
|
|
|
| Secondary | Change From Baseline in Blood Urea Nitrogen, Cholesterol, Chloride, Potassium, and Sodium at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Safety Population: all participants who received at least one dose of study medication. Week 16 (Last observation carried forward [LOCF]) = 62 participants; Week 52 (Observed case [OC]) = 44 participants | Posted | Mean | Standard Deviation | millimoles per Liter (MMOL/L) | Baseline (Screening) and Weeks 16 and 52 |
|
|
|
| Secondary | Change From Baseline in Prolactin at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Safety Population: all participants who received at least one dose of study medication. Week 16 (Last observation carried forward [LOCF]) = 62 participants; Week 52 (Observed case [OC]) = 44 participants | Posted | Mean | Standard Deviation | micrograms per Liter (MCG/L) | Baseline (Screening) and Weeks 16 and 52 |
|
|
|
| Secondary | Change From Baseline in Hematocrit at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Safety Population: all participants who received at least one dose of study medication. Week 16 (Last observation carried forward [LOCF]) = 62 participants; Week 52 (Observed case [OC]) = 44 participants | Posted | Mean | Standard Deviation | proportion of 1 (SI) | Baseline (Screening) and Weeks 16 and 52 |
|
|
|
| Secondary | Change From Baseline in Platelet Count and White Blood Cell Count at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Safety Population: all participants who received at least one dose of study medication. Week 16 (Last observation carried forward [LOCF]) = 62 participants; Week 52 (Observed case [OC]) = 44 participants | Posted | Mean | Standard Deviation | giga per Liter (GI/L) | Baseline (Screening) and Weeks 16 and 52 |
|
|
|
| Secondary | Change From Baseline in Red Blood Cell Count at Weeks 16 and 52 | Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. | Safety Population: all participants who received at least one dose of study medication. Week 16 (Last observation carried forward [LOCF]) = 62 participants; Week 52 (Observed case [OC]) = 44 participants | Posted | Mean | Standard Deviation | tera per Liter (TI/L) | Baseline (Screening) and Weeks 16 and 52 |
|
|
|
| Secondary | Urinalysis Data | The number of participants with the indicated dipstick test values were measured. Dipstick test values: Neg Value, Trace, +1, +2, +3, +4. No participants had a score of +5. | Safety Population: Screening Week 16 (LOCF) = 62 participants; Week 52 (OC) = 44 participants | Posted | Number | participants | Screening, Week 16, and Week 52 |
|
|
|
| Secondary | Number of Participants With the Indicated Shift From Baseline in 12-Lead Electrocardiogram (ECG) Findings at Weeks 16 and 52 | Baseline Finding/Time Period Finding. Abbreviations: N = normal; A = abnormal; CS = clinically significant; NCS = not clinically significant. Options include N/N, N/ANCS, N/ACS, ANCS/N, ANCS/ANCS, ANCS/ACS, ACS/N, ACS/ANCS, and ACS/ACS. | Safety Population: Week 16 (LOCF) = 62 participants; Week 52 (OC) = 44 participants | Posted | Number | participants | Baseline (Screening) and Weeks 16 and 52 |
|
|
|
| Secondary | Change From Baseline in Supine and Standing Systolic and Diastolic Blood Pressure at Weeks 16 and 52 | Change from baseline was calculated as Week 16 and Week 52 values minus baseline values. | Safety Population: Week 16 (LOCF) = 62 participants; Week 52 (OC) = 44 participants | Posted | Mean | Standard Deviation | millimeters of mercury (mmHg) | Baseline (Screening) and Weeks 16 and 52 |
|
|
|
| Secondary | Change From Baseline in Supine and Standing Pulse Rate at Weeks 16 and 52 | Change from baseline was calculated as Week 16 and Week 52 values minus baseline values. | Safety Population: Week 16 (LOCF) = 62 participants; Week 52 (OC) = 44 participants | Posted | Mean | Standard Deviation | beats per minute (bpm) | Baseline (Screening) and Weeks 16 and 52 |
|
|
|
| 5 |
| 62 |
| 51 |
| 62 |
| EG001 | Ropinirole PR/XR (Taper Phase) | The dose was tapered over 2 to 3 weeks according to the maintenance dose at completion of the Treatment Phase (or withdrawal) | 1 | 62 | 0 | 62 |
| Small intestine carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
|
| Intestinal obstruction | Gastrointestinal disorders | MedDRA | Systematic Assessment |
|
| Anti-neutrophil cytoplasmic antibody positive vasculitis | Immune system disorders | MedDRA | Systematic Assessment |
|
| Cerebral infarction | Nervous system disorders | MedDRA | Systematic Assessment |
|
| Glomerulonephritis rapidly progressive | Renal and urinary disorders | MedDRA | Systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA | Systematic Assessment |
|
| Stomach discomfort | Gastrointestinal disorders | MedDRA | Systematic Assessment |
|
| Somnolence | Nervous system disorders | MedDRA | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA | Systematic Assessment |
|
| Hallucination | Psychiatric disorders | MedDRA | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA | Systematic Assessment |
|
| Bronchitis | Infections and infestations | MedDRA | Systematic Assessment |
|
| Edema peripheral | General disorders | MedDRA | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA | Systematic Assessment |
|
GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
| Title | Measurements |
|---|---|
|
| Week 3, n=60 |
|
| Week 4, n=58 |
|
| Week 6, n=57 |
|
| Week 8, n=56 |
|
| Week 10, n=57 |
|
| Week 12, n=56 |
|
| Week 16, n=54 |
|
| Final Assessment Point (Up to Week 16), n=62 |
|
| Week 20, n=53 |
|
| Week 24, n=51 |
|
| Week 28, n=48 |
|
| Week 32, n=47 |
|
| Week 36, n=47 |
|
| Week 40, n=45 |
|
| Week 44, n=45 |
|
| Week 48, n=44 |
|
| Week 52, n=44 |
|
| Title | Measurements |
|---|---|
|
| Week 4, n=58 |
|
| Week 6, n=57 |
|
| Week 8, n=56 |
|
| Week 10, n=57 |
|
| Week 12, n=56 |
|
| Week 16, n=54 |
|
| Final Assessment Point (Up to Week 16), n=62 |
|
| Week 20, n=53 |
|
| Week 24, n=51 |
|
| Week 28, n=48 |
|
| Week 32, n=47 |
|
| Week 36, n=47 |
|
| Week 40, n=45 |
|
| Week 44, n=45 |
|
| Week 48, n=44 |
|
| Week 52, n=44 |
|
| Title | Measurements |
|---|---|
|
| Week 4, n=58 |
|
| Week 6, n=57 |
|
| Week 8, n=56 |
|
| Week 10, n=57 |
|
| Week 12, n=56 |
|
| Week 16, n=54 |
|
| Final Assessment Point (Up to Week 16), n=62 |
|
| Week 20, n=53 |
|
| Week 24, n=51 |
|
| Week 28, n=48 |
|
| Week 32, n=47 |
|
| Week 36, n=47 |
|
| Week 40, n=45 |
|
| Week 44, n=45 |
|
| Week 48, n=44 |
|
| Week 52, n=44 |
|
| Title | Measurements |
|---|---|
|
| Week 4, n=58 |
|
| Week 6, n=57 |
|
| Week 8, n=56 |
|
| Week 10, n=57 |
|
| Week 12, n=56 |
|
| Week 16, n=54 |
|
| Final Assessment Point (Up to Week 16), n=62 |
|
| Week 20, n=53 |
|
| Week 24, n=51 |
|
| Week 28, n=48 |
|
| Week 32, n=47 |
|
| Week 36, n=47 |
|
| Week 40, n=45 |
|
| Week 44, n=45 |
|
| Week 48, n=44 |
|
| Week 52, n=44 |
|
| Title | Measurements |
|---|---|
|
| Week 3, n=60 |
|
| Week 4, n=58 |
|
| Week 6, n=57 |
|
| Week 8, n=56 |
|
| Week 10, n=57 |
|
| Week 12, n=56 |
|
| Week 16, n=54 |
|
| Final Assessment Point (Up to Week 16), n=62 |
|
| Week 20, n=53 |
|
| Week 24, n=51 |
|
| Week 28, n=48 |
|
| Week 32, n=47 |
|
| Week 36, n=47 |
|
| Week 40, n=45 |
|
| Week 44, n=45 |
|
| Week 48, n=44 |
|
| Week 52, n=44 |
|
| Title | Measurements |
|---|---|
|
| Week 4, n=58 |
|
| Week 6, n=57 |
|
| Week 8, n=56 |
|
| Week 10, n=57 |
|
| Week 12, n=56 |
|
| Week 16, n=54 |
|
| Final Assessment Point (Up to Week 16), n=62 |
|
| Week 20, n=53 |
|
| Week 24, n=51 |
|
| Week 28, n=48 |
|
| Week 32, n=47 |
|
| Week 36, n=47 |
|
| Week 40, n=45 |
|
| Week 44, n=45 |
|
| Week 48, n=44 |
|
| Week 52, n=44 |
|
| Title | Measurements |
|---|---|
|
| Week 4, n=28 |
|
| Week 6, n=27 |
|
| Week 8, n=27 |
|
| Week 10, n=27 |
|
| Week 12, n=26 |
|
| Week 16, n=24 |
|
| Final Assessment Point (Up to Week 16), n=30 |
|
| Week 20, n=23 |
|
| Week 24, n=22 |
|
| Week 28, n=20 |
|
| Week 32, n=19 |
|
| Week 36, n=19 |
|
| Week 40, n=17 |
|
| Week 44, n=17 |
|
| Week 48, n=16 |
|
| Week 52, n=16 |
|
| Title | Measurements |
|---|---|
|
| Week 3, n=60 |
|
| Week 4, n=58 |
|
| Week 6, n=57 |
|
| Week 8, n=56 |
|
| Week 10, n=57 |
|
| Week 12, n=56 |
|
| Week 16, n=54 |
|
| Final Assessment Point (Up to Week 16), n=62 |
|
| Week 20, n=53 |
|
| Week 24, n=51 |
|
| Week 28, n=48 |
|
| Week 32, n=47 |
|
| Week 36, n=47 |
|
| Week 40, n=45 |
|
| Week 44, n=45 |
|
| Week 48, n=44 |
|
| Week 52, n=44 |
|
|
| SKF104557 (metabolite), fasted |
|
| SKF89124 (metabolite), fed |
|
| SKF89124 (metabolite), fasted |
|
|
|
| SKF101468 (ropinirole), 8 mg, n=61 |
|
| SKF101468 (ropinirole), 10 mg, n=17 |
|
| SKF101468 (ropinirole), 12 mg, n=12 |
|
| SKF101468 (ropinirole), 14 mg, n=9 |
|
| SKF101468 (ropinirole), 16 mg, n=12 |
|
| SKF104557 (metabolite), 2 mg, n=61 |
|
| SKF104557 (metabolite), 4 mg, n=58 |
|
| SKF104557 (metabolite), 6 mg, n=1 |
|
| SKF104557 (metabolite), 8 mg, n=61 |
|
| SKF104557 (metabolite), 10 mg, n=17 |
|
| SKF104557 (metabolite), 12 mg, n=12 |
|
| SKF104557 (metabolite), 14 mg, n=9 |
|
| SKF104557 (metabolite), 16 mg, n=12 |
|
| SKF89124 (metabolite), 2 mg, n=61 |
|
| SKF89124 (metabolite), 4 mg, n=58 |
|
| SKF89124 (metabolite), 6 mg, n=1 |
|
| SKF89124 (metabolite), 8 mg, n=61 |
|
| SKF89124 (metabolite), 10 mg, n=17 |
|
| SKF89124 (metabolite), 12 mg, n=12 |
|
| SKF89124 (metabolite), 14 mg, n=9 |
|
| SKF89124 (metabolite), 16 mg, n=12 |
|
| Title | Measurements |
|---|---|
|
| Week 4, n=58 |
|
| Week 6, n=57 |
|
| Week 8, n=56 |
|
| Week 10, n=57 |
|
| Week 12, n=56 |
|
| Week 16, n=54 |
|
| Final Assessment Point (Up to Week 16), n=62 |
|
| Week 20, n=53 |
|
| Week 24, n=51 |
|
| Week 28, n=48 |
|
| Week 32, n=47 |
|
| Week 36, n=47 |
|
| Week 40, n=45 |
|
| Week 44, n=45 |
|
| Week 48, n=44 |
|
| Week 52, n=44 |
|
| Title | Measurements |
|---|---|
|
| Week 4, n=56 |
|
| Week 6, n=55 |
|
| Week 8, n=54 |
|
| Week 10, n=55 |
|
| Week 12, n=54 |
|
| Week 16, n=52 |
|
| Final Assessment Point (Up to Week 16), n=60 |
|
| Week 20, n=51 |
|
| Week 24, n=49 |
|
| Week 28, n=46 |
|
| Week 32, n=45 |
|
| Week 36, n=45 |
|
| Week 40, n=43 |
|
| Week 44, n=43 |
|
| Week 48, n=42 |
|
| Week 52, n=42 |
|
| Title | Measurements |
|---|---|
|
| Week 3, n=60 |
|
| Week 4, n=58 |
|
| Week 6, n=57 |
|
| Week 8, n=56 |
|
| Week 10, n=57 |
|
| Week 12, n=56 |
|
| Week 16, n=54 |
|
| Final Assessment Point (Up to Week 16), n=62 |
|
| Week 20, n=53 |
|
| Week 24, n=51 |
|
| Week 28, n=48 |
|
| Week 32, n=47 |
|
| Week 36, n=47 |
|
| Week 40, n=45 |
|
| Week 44, n=45 |
|
| Week 48, n=44 |
|
| Week 52, n=44 |
|
| Title | Measurements |
|---|---|
|
| Week 4, n=58 |
|
| Week 6, n=57 |
|
| Week 8, n=56 |
|
| Week 10, n=57 |
|
| Week 12, n=56 |
|
| Week 16, n=54 |
|
| Final Assessment Point (Up to Week 16), n=62 |
|
| Week 20, n=53 |
|
| Week 24, n=51 |
|
| Week 28, n=48 |
|
| Week 32, n=47 |
|
| Week 36, n=47 |
|
| Week 40, n=45 |
|
| Week 44, n=45 |
|
| Week 48, n=44 |
|
| Week 52, n=44 |
|
| Title | Measurements |
|---|---|
|
| Week 4, n=19 |
|
| Week 6, n=18 |
|
| Week 8, n=17 |
|
| Week 10, n=18 |
|
| Week 12, n=17 |
|
| Week 16, n=16 |
|
| Final Assessment Point (Up to Week 16), n=21 |
|
| Week 20, n=15 |
|
| Week 24, n=14 |
|
| Week 28, n=13 |
|
| Week 32, n=13 |
|
| Week 36, n=13 |
|
| Week 40, n=12 |
|
| Week 44, n=12 |
|
| Week 48, n=12 |
|
| Week 52, n=12 |
|
| Title | Measurements |
|---|---|
|
| Screening, Stage 2 |
|
| Screening, Stage 2.5 |
|
| Screening, Stage 3 |
|
| Week 0, Stage 0 |
|
| Week 0, Stage 1 |
|
| Week 0, Stage 1.5 |
|
| Week 0, Stage 2 |
|
| Week 0, Stage 2.5 |
|
| Week 0, Stage 3 |
|
| Week 1, Stage 0 |
|
| Week 1, Stage 1 |
|
| Week 1, Stage 1.5 |
|
| Week 1, Stage 2 |
|
| Week 1, Stage 2.5 |
|
| Week 1, Stage 3 |
|
| Week 2, Stage 0 |
|
| Week 2, Stage 1 |
|
| Week 2, Stage 1.5 |
|
| Week 2, Stage 2 |
|
| Week 2, Stage 2.5 |
|
| Week 2, Stage 3 |
|
| Week 3, Stage 0 |
|
| Week 3, Stage 1 |
|
| Week 3, Stage 1.5 |
|
| Week 3, Stage 2 |
|
| Week 3, Stage 2.5 |
|
| Week 3, Stage 3 |
|
| Week 4, Stage 0 |
|
| Week 4, Stage 1 |
|
| Week 4, Stage 1.5 |
|
| Week 4, Stage 2 |
|
| Week 4, Stage 2.5 |
|
| Week 4, Stage 3 |
|
| Week 6, Stage 0 |
|
| Week 6, Stage 1 |
|
| Week 6, Stage 1.5 |
|
| Week 6, Stage 2 |
|
| Week 6, Stage 2.5 |
|
| Week 6, Stage 3 |
|
| Week 8, Stage 0 |
|
| Week 8, Stage 1 |
|
| Week 8, Stage 1.5 |
|
| Week 8, Stage 2 |
|
| Week 8, Stage 2.5 |
|
| Week 8, Stage 3 |
|
| Week 10, Stage 0 |
|
| Week 10, Stage 1 |
|
| Week 10, Stage 1.5 |
|
| Week 10, Stage 2 |
|
| Week 10, Stage 2.5 |
|
| Week 10, Stage 3 |
|
| Week 12, Stage 0 |
|
| Week 12, Stage 1 |
|
| Week 12, Stage 1.5 |
|
| Week 12, Stage 2 |
|
| Week 12, Stage 2.5 |
|
| Week 12, Stage 3 |
|
| Week 16, Stage 0 |
|
| Week 16, Stage 1 |
|
| Week 16, Stage 1.5 |
|
| Week 16, Stage 2 |
|
| Week 16, Stage 2.5 |
|
| Week 16, Stage 3 |
|
| Final Assessment Point (Up to Week 16), Stage 0 |
|
| Final Assessment Point (Up to Week 16), Stage 1 |
|
| Final Assessment Point (Up to Week 16), Stage 1.5 |
|
| Final Assessment Point (Up to Week 16), Stage 2 |
|
| Final Assessment Point (Up to Week 16), Stage 2.5 |
|
| Final Assessment Point (Up to Week 16), Stage 3 |
|
| Week 20, Stage 0 |
|
| Week 20, Stage 1 |
|
| Week 20, Stage 1.5 |
|
| Week 20, Stage 2 |
|
| Week 20, Stage 2.5 |
|
| Week 20, Stage 3 |
|
| Week 24, Stage 0 |
|
| Week 24, Stage 1 |
|
| Week 24, Stage 1.5 |
|
| Week 24, Stage 2 |
|
| Week 24, Stage 2.5 |
|
| Week 24, Stage 3 |
|
| Week 28, Stage 0 |
|
| Week 28, Stage 1 |
|
| Week 28, Stage 1.5 |
|
| Week 28, Stage 2 |
|
| Week 28, Stage 2.5 |
|
| Week 28, Stage 3 |
|
| Week 32, Stage 0 |
|
| Week 32, Stage 1 |
|
| Week 32, Stage 1.5 |
|
| Week 32, Stage 2 |
|
| Week 32, Stage 2.5 |
|
| Week 32, Stage 3 |
|
| Week 36, Stage 0 |
|
| Week 36, Stage 1 |
|
| Week 36, Stage 1.5 |
|
| Week 36, Stage 2 |
|
| Week 36, Stage 2.5 |
|
| Week 36, Stage 3 |
|
| Week 40, Stage 0 |
|
| Week 40, Stage 1 |
|
| Week 40, Stage 1.5 |
|
| Week 40, Stage 2 |
|
| Week 40, Stage 2.5 |
|
| Week 40, Stage 3 |
|
| Week 44, Stage 0 |
|
| Week 44, Stage 1 |
|
| Week 44, Stage 1.5 |
|
| Week 44, Stage 2 |
|
| Week 44, Stage 2.5 |
|
| Week 44, Stage 3 |
|
| Week 48, Stage 0 |
|
| Week 48, Stage 1 |
|
| Week 48, Stage 1.5 |
|
| Week 48, Stage 2 |
|
| Week 48, Stage 2.5 |
|
| Week 48, Stage 3 |
|
| Week 52, Stage 0 |
|
| Week 52, Stage 1 |
|
| Week 52, Stage 1.5 |
|
| Week 52, Stage 2 |
|
| Week 52, Stage 2.5 |
|
| Week 52, Stage 3 |
|
| Title | Measurements |
|---|---|
|
| Week 4, n=58 |
|
| Week 6, n=57 |
|
| Week 8, n=56 |
|
| Week 10, n=57 |
|
| Week 12, n=56 |
|
| Week 16, n=54 |
|
| Final Assessment Point (Up to Week 16), n=62 |
|
| Week 20, n=53 |
|
| Week 24, n=51 |
|
| Week 28, n=48 |
|
| Week 32, n=47 |
|
| Week 36, n=47 |
|
| Week 40, n=45 |
|
| Week 44, n=45 |
|
| Week 48, n=44 |
|
| Week 52, n=44 |
|
| Title | Measurements |
|---|
|
| Day 21 |
|
| Day 28 |
|
| Day 70 |
|
| Day 84 |
|
| Day 96 |
|
| Day 112 |
|
| Day 140 |
|
| Day 168 |
|
| Day 175 |
|
| Day 183 |
|
| Day 196 |
|
| Day 239 |
|
| Day 252 |
|
| Day 315 |
|
| Day 359 |
|
| Day 364 |
|
| Title | Measurements |
|---|---|
|
| Total Protein, Week 52 |
|
| Hemoglobin, Week 16 |
|
| Hemoglobin, Week 52 |
|
|
| Alanine Amino Transferase, Week 52 |
|
| Aspartate Amino Transferase, Week 16 |
|
| Aspartate Amino Transferase, Week 52 |
|
| Creatine Kinase, Week 16 |
|
| Creatine Kinase, Week 52 |
|
| Gamma Glutamyl transferase, Week 16 |
|
| Gamma Glutamyl transferase, Week 52 |
|
| Lactate Dehydrogenase, Week 16 |
|
| Lactate Dehydrogenase, Week 52 |
|
| Title | Measurements |
|---|---|
|
| Creatinine, Week 52 |
|
| Title | Measurements |
|---|---|
|
| Cholesterol, Week 52 |
|
| Chloride, Week 16 |
|
| Chloride, Week 52 |
|
| Potassium, Week 16 |
|
| Potassium, Week 52 |
|
| Sodium, Week 16 |
|
| Sodium, Week 52 |
|
| Title | Measurements |
|---|---|
|
| White Blood Cell Count, Week 52 |
|
| Title | Measurements |
|---|---|
|
| Urine Occult Blood - Screening: +2 |
|
| Urine Occult Blood - Screening: +3 |
|
| Urine Occult Blood - Screening: +4 |
|
| Urine Occult Blood - Week 16: Neg Value |
|
| Urine Occult Blood - Week 16: Trace |
|
| Urine Occult Blood - Week 16: +1 |
|
| Urine Occult Blood - Week 16: +2 |
|
| Urine Occult Blood - Week 16: +3 |
|
| Urine Occult Blood - Week 16: +4 |
|
| Urine Occult Blood - Week 52: Neg Value |
|
| Urine Occult Blood - Week 52: Trace |
|
| Urine Occult Blood - Week 52: +1 |
|
| Urine Occult Blood - Week 52: +2 |
|
| Urine Occult Blood - Week 52: +3 |
|
| Urine Occult Blood - Week 52: +4 |
|
| Urine Glucose - Screening: Neg Value |
|
| Urine Glucose - Screening: Trace |
|
| Urine Glucose - Screening: +1 |
|
| Urine Glucose - Screening: +2 |
|
| Urine Glucose - Screening: +3 |
|
| Urine Glucose - Screening: +4 |
|
| Urine Glucose - Week 16: Neg Value |
|
| Urine Glucose - Week 16: Trace |
|
| Urine Glucose - Week 16: +1 |
|
| Urine Glucose - Week 16: +2 |
|
| Urine Glucose - Week 16: +3 |
|
| Urine Glucose - Week 16: +4 |
|
| Urine Glucose - Week 52: Neg Value |
|
| Urine Glucose - Week 52: Trace |
|
| Urine Glucose - Week 52: +1 |
|
| Urine Glucose - Week 52: +2 |
|
| Urine Glucose - Week 52: +3 |
|
| Urine Glucose - Week 52: +4 |
|
| Urine Protein - Screening: Neg Value |
|
| Urine Protein - Screening: Trace |
|
| Urine Protein - Screening: +1 |
|
| Urine Protein - Screening: +2 |
|
| Urine Protein - Screening: +3 |
|
| Urine Protein - Screening: +4 |
|
| Urine Protein - Week 16: Neg Value |
|
| Urine Protein - Week 16: Trace |
|
| Urine Protein - Week 16: +1 |
|
| Urine Protein - Week 16: +2 |
|
| Urine Protein - Week 16: +3 |
|
| Urine Protein - Week 16: +4 |
|
| Urine Protein - Week 52: Neg Value |
|
| Urine Protein - Week 52: Trace |
|
| Urine Protein - Week 52: +1 |
|
| Urine Protein - Week 52: +2 |
|
| Urine Protein - Week 52: +3 |
|
| Urine Protein - Week 52: +4 |
|
| Urine Urobilinogen - Screening: Neg Value |
|
| Urine Urobilinogen - Screening: Trace |
|
| Urine Urobilinogen - Screening: +1 |
|
| Urine Urobilinogen - Screening: +2 |
|
| Urine Urobilinogen - Screening: +3 |
|
| Urine Urobilinogen - Screening: +4 |
|
| Urine Urobilinogen - Week 16: Neg Value |
|
| Urine Urobilinogen - Week 16: Trace |
|
| Urine Urobilinogen - Week 16: +1 |
|
| Urine Urobilinogen - Week 16: +2 |
|
| Urine Urobilinogen - Week 16: +3 |
|
| Urine Urobilinogen - Week 16: +4 |
|
| Urine Urobilinogen - Week 52: Neg Value |
|
| Urine Urobilinogen - Week 52: Trace |
|
| Urine Urobilinogen - Week 52: +1 |
|
| Urine Urobilinogen - Week 52: +2 |
|
| Urine Urobilinogen - Week 52: +3 |
|
| Urine Urobilinogen - Week 52: +4 |
|
| Title | Measurements |
|---|---|
|
| Baseline: ANCS; Week 16: N |
|
| Baseline: ANCS; Week 16: ANCS |
|
| Baseline: ANCS; Week 16: ACS |
|
| Baseline: ACS; Week 16: N |
|
| Baseline: ACS; Week 16: ANCS |
|
| Baseline: ACS; Week 16: ACS |
|
| Baseline: N; Week 52: N |
|
| Baseline: N; Week 52: ANCS |
|
| Baseline: N; Week 52: ACS |
|
| Baseline: ANCS; Week 52: N |
|
| Baseline: ANCS; Week 52: ANCS |
|
| Baseline: ANCS; Week 52: ACS |
|
| Baseline: ACS; Week 52: N |
|
| Baseline: ACS; Week 52: ANCS |
|
| Baseline: ACS; Week 52: ACS |
|
| Title | Measurements |
|---|---|
|
| Supine Diastolic BP - Week 52 |
|
| Standing Systolic BP - Week 16 |
|
| Standing Systolic BP - Week 52 |
|
| Standing Diastolic BP - Week 16 |
|
| Standing Diastolic BP - Week 52 |
|
| Title | Measurements |
|---|---|
|
| Standing Heart Rate - Week 52 |
|